Get the Weekly Intelligence Brief — top committee picks every Sunday.
BNTX · NASDAQ · STOCK

BioNTech SE

Healthcare Updated August 11, 2026
$92.76
52W $79.52 – $124.00
66/100
$23.31B
-11.8
1.28
AI Committee Verdict
Buy
66/100
Conviction: Contested · 50% agreement · 4 analysts
Contested

Is BNTX Bullish or Bearish?

Bullish. Innellis AI committee rates BioNTech SE (BNTX) Buy with a composite score of 66/100 , based on 4 analysts with 50% agreement. Last updated August 11, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +9.17 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -10.83 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.

Bull & Bear Case

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • VIX regime is low -- calm backdrop supports risk-taking — Macro
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
Insufficient data for bear case.
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 11, 2026
Overall Committee Score
66/100
Agreement
50%
Analysts
4
Conviction
Contested
Sector Rank
Top 15%
of 192 Healthcare peers
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst bullish
70 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst bullish
78 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Technical Analysis

RSI (14)
54.0
Neutral
MACD Histogram
0.127
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$91.18
Resistance
$98.79
Bollinger %B
0.71
Inside Bands
Price vs Moving Averages
EMA 9
$92.34 Above
EMA 21
$92.10 Above
EMA 50
$92.33 Above
EMA 200
$96.97 Below

Fundamental Analysis

Valuation
100
Profitability
25
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio -11.8×
P/B Ratio 1.13×
PEG Ratio 0.12
Dividend Yield 0.00%
52W High $124.00
52W Low $79.52
Quality & Growth
ROE -567.9%
ROA -496.5%
Gross Margin 6894.9%
Operating Margin -6463.2%
Revenue Growth YoY
Debt / Equity 0.02
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -11.8 (inexpensive relative to a 15-40x range); Price-to-book of 1.1x; PEG ratio of 0.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -5.7%; Return on assets of -5.0%; Net margin of -64.2%; Gross margin of 68.9%; Current ratio of 7.85 (healthy short-term liquidity); Debt-to-equity of 0.02; Free cash flow per share is positive (2.05); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full BNTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore BNTX Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime